Philip Morris International clinical trials

Also known as PMI.

The registry lists 55 studies whose lead sponsor is Philip Morris International or one of 3 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 31, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 55. Browse all 55 →

• Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THSActive, not recruitingNCT07108166Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device VariantsActive, not recruitingNCT07443631Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette SmokingCompletedNCT05385055

  Sponsor listed in the registry: Philip Morris Products S.A.

• Pharmacokinetics and Pharmacodynamics of THS With LEVIA Compared to THS With TEREA and to CigarettesCompletedNCT07459712Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Tablet (NICOTINE TABLET) on AttentionCompletedNCT07408180Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.CompletedNCT03837704Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetics and Pharmacodynamics of Two Variants of VM 1.0 Compared to Cigarettes in Adult Current SmokersActive, not recruitingNCT07135648Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)CompletedNCT01959607Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification StudyCompletedNCT01780298

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIGCompletedNCT05789420Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic DiseaseWithdrawnNCT05566678Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy SmokersCompletedNCT05317195Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.TerminatedNCT05569005Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THSCompletedNCT05599451Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Japanese Post-Market Cohort StudyTerminatedNCT03020667

  Sponsor listed in the registry: Philip Morris Products S.A.

• Randomized Controlled Trial to Evaluate the Impact of ZYN Nicotine Pouch Products on Cigarette Usage and BoExp in Adult Smokers Over a 12-week PeriodCompletedNCT06568900Not applicable

  Sponsor listed in the registry: Swedish Match AB · First submitted after Swedish Match AB became part of Philip Morris International

• Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)CompletedNCT06171490Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking CigarettesCompletedNCT05383508Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking AbstinenceCompletedNCT05487456Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Cross-Sectional Survey on the Use of Tobacco Products - London (UK)TerminatedNCT03527030

  Sponsor listed in the registry: Philip Morris Products S.A.

• Cross-Sectional Survey on the Use of Tobacco Products - ItalyTerminatedNCT03527004

  Sponsor listed in the registry: Philip Morris Products S.A.

• Cross-Sectional Survey on the Use of Tobacco Products - GermanyTerminatedNCT03527017

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.CompletedNCT02641587Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking CessationCompletedNCT02432729

  Sponsor listed in the registry: Philip Morris Products S.A.

• Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment OutcomeCompletedNCT03364751Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.CompletedNCT02503254Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 WeeksCompletedNCT02396381Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Effect of Switching From Cigarette Smoking to IQOS on Exercise CapacityCompletedNCT03887117Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to itCompletedNCT03953183Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2CompletedNCT02649556Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping ProcedureCompletedNCT03086707Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetic Profile of the CHTP 1.1 MCompletedNCT02466412Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory SettingCompletedNCT01989156Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory SettingCompletedNCT01970995Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)CompletedNCT01967719Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).CompletedNCT01967706Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)CompletedNCT01967732Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement SettingCompletedNCT01970982Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.CompletedNCT01959932Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3LCompletedNCT02532374Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3PCompletedNCT03369340Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 VariantsCompletedNCT03379740Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Exploratory THS 2.1 Biomarkers of Exposure StudyCompletedNCT01780714Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety StudyCompletedNCT01780688Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• European Exposure StudyCompletedNCT01237912

  Sponsor listed in the registry: Philip Morris Products S.A.

• Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking ArticleCompletedNCT00812279Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette SmokersCompletedNCT02103751

  Sponsor listed in the registry: Philip Morris Products S.A.

• Real-Life Passive Exposure Assessment of IQOSCompletedNCT03550989

  Sponsor listed in the registry: Philip Morris Products S.A.

• User Acceptability of a Nicotine Lactate Delivery System (P3L)CompletedNCT02643693Not applicable

  Sponsor listed in the registry: Philip Morris Products S.A.

• Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine LozengesCompletedNCT03432273Phase 1

  Sponsor listed in the registry: Fertin Pharma A/S · First submitted before Fertin Pharma A/S became part of Philip Morris International